News | November 14, 2022
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
The event is supported by the Ministry of Commerce & Industry, Government of India and CDSCO, Ministry of Health.
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Subscribe To Our Newsletter & Stay Updated
